Silence Therapeutics and Merck
Merck KGaA, Darmstadt, Germany to acquire Silence Therapeutics for $1.3 billion
Company-confirmed: reported in the company's own SEC filing
Latest update Oct 19, 2026, 8:05 AM ET
- ✓Announced
- 2Pending
- 3Completed
Acquirer
MerckMRKTarget
Silence TherapeuticsSLN- Deal value
- $1.3B
- as stated in the filing
- Offer
- $20.00
- cash
- Premium
- +130.41%
- $20.00 per share in cash against the 2026-10-16 close of $8.68
- Expected close
- first quarter of 2027
- business combination
The offer against the share price
Last close before the disclosure and the cash price per share written in the filing.
+130.4% premium over that close
Share prices around the disclosure
Daily closes, each set to 100 on the first day shown. The dashed lines mark the session that first reflects each public event.

